Skip to content

Dense Breasts, Family History and Your Mammogram: How to Know your Real Risk

unPAUSED with Dr. Mary Claire Haver

Hosted by Dr. Mary Claire Haver

37m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This episode covers breast cancer risk assessment, genetic testing, and the complex decisions surrounding hormone therapy, family history, and cancer survivorship. Dr. Mary Claire Haver and Dr. Eleonora Teplinsky discuss common misconceptions about family history and genetics, explaining that only five to ten percent of breast cancers are hereditary. They examine tools like the Tyrer-Cuzick risk model, direct-to-consumer blood tests and whole-body MRIs, and the distinct risks posed by dense breast tissue. The conversation also addresses the realities of surgical menopause for pre-vivers, the impact of treatments on bone density and heart health, and coping with cognitive changes and body image struggles after a diagnosis.

  • Most breast cancers are not hereditary, as only five to ten percent of cases are linked to inherited genes. 1:58
  • Breast cancer risk assessment should begin at age twenty-five using validated models like the Tyrer-Cuzick calculator. 2:48
  • Women with dense breast tissue face both an increased risk of cancer and a higher chance of missed detections on mammograms. 12:14
  • Pre-vivers who undergo risk-reducing oophorectomy can often safely use hormone replacement therapy after individual counseling. 17:22
  • Anyone receiving chemotherapy should obtain a baseline bone density scan to monitor and protect skeletal health. 24:33

Chapters

  1. 0:04
    Episode Introduction and Host Overview

    The host introduces the podcast, its purpose, and the guest’s background.

  2. 0:41
    Misconceptions About Family History and Estrogen

    Discussion of how family history is misunderstood and its impact on hormone use.

  3. 2:45
    Defining Genetic Risk and Screening Protocols

    Explains hereditary cancer syndromes, genetic testing thresholds, and supplemental imaging.

  4. 8:02
    Direct-to-Consumer Tests and Their Limitations

    Critique of full-body MRI and blood-based tests like Galleri for cancer screening.

  5. 17:47
    Hormone Therapy for Pre-Vivers and BRCA Carriers

    Explores safe hormone use after prophylactic oophorectomy in high-risk women.

  6. 23:24
    Equity in Genetic Testing for Women of Color

    Highlights disparities in testing, variant interpretation, and risk assessment.

  7. 26:16
    Bone Health and Chemotherapy-Induced Osteoporosis

    Discusses baseline bone density scans, lifestyle strategies, and medication options.

  8. 27:26
    Chemo Brain and Cognitive Side Effects

    Describes the cognitive impact of cancer treatment and the lack of routine testing.

  9. 29:43
    Cardiovascular Risks from Cancer Treatments

    Details how radiation, chemo, and hormonal changes affect heart health.

  10. 31:47
    Mental Health Support and Community Resources

    Emphasizes the role of support groups, counseling, and body image education.

  11. 35:35
    Key Takeaways and Listener Action Items

    Summarizes main points and practical steps listeners can take before their next appointment.

Highlights

  • 1:08

    Family History Misconceptionsinsight

    The guest explains that a single older relative with breast cancer differs significantly from multiple young relatives, which usually suggests a hereditary syndrome.

  • 3:03

    Risk Assessment Toolsstrategy

    The guest outlines the publicly available Tyrer-Cuzick model, which incorporates factors like family history, age of first period, and breast density.

  • 5:27

    Non-BRCA Genetic Risksdata

    Beyond the well-known BRCA genes, mutations in genes such as CHK2, ATM, and PALB2 also increase cancer risk and guide screening protocols.

  • 11:26

    AI Mammogram Risk Assessmentinsight

    New AI-based risk assessment tools like Clarity are being piloted to predict a patient's five-year breast cancer risk from a single mammogram image.

  • 16:07

    Mammogram Radiation Equivalenceinsight

    The radiation exposure from a mammogram is equal to roughly six or seven weeks of normal background radiation from walking outside.

  • 18:27

    Hormone Therapy for Pre-viversdata

    Recent research demonstrates that BRCA mutation carriers who keep their breasts intact after having their ovaries removed do not increase their breast cancer risk by taking hormone therapy.

  • 28:28

    Chemo Brain and Cognitive Testingdebate

    Standard cognitive tests often fail to detect cancer-related cognitive impairment in high-functioning professionals because baseline cognitive function is never tested.

Quotes

  • “Five to 10 of breast cancers are hereditary.”
    Unnamed speaker · 1:58
  • “Carrying a BRCA mutation has an up to 80% risk of being diagnosed with breast cancer.”
    Unnamed speaker · 7:00
  • “We should be thinking about that or at least having the conversation.”
    Unnamed speaker · 20:50
  • “If you go into premature menopause, especially before the age of 45, you are higher risks of cardiovascular and cognitive and musculoskeletal health.”
    Unnamed speaker · 21:29
  • Jones Road Beauty 13:37–15:21
  • Pura 15:22–15:53

About this episode

In part two, Dr. Mary Claire Haver and breast oncologist Dr. Eleonora Teplinsky shift to breast cancer risk, prevention, and early detection: dense breasts, family history myths (only 5–10% of breast cancers are hereditary), risk assessment from age 25, who needs genetic testing, and why previvors in surgical menopause can use hormone therapy without raising their breast cancer risk. Plus life after treatment — bone density, chemo brain, heart health, fear of recurrence, and body image after mastectomy. Guest links: Dr. Eleonora Teplinsky (Website) https://interludecancerstories.com/ Dr. Eleonora Teplinsky (Instagram) https://www.instagram.com/drteplinsky/ Dr. Eleonora Teplinsky (Substack) https://drteplinsky.substack.com/ Dr. Eleonora Teplinsky (TikTok) https://www.tiktok.com/@drteplinsky Dr. Eleonora Teplinsky (Facebook) https://www.facebook.com/drteplinsky/ Dr. Eleonora Teplinsky (LinkedIn) https://www.linkedin.com/in/eleonora-teplinsky-md-fasco-220aa02 Dr. Eleonora Teplinsky (YouTube) https://www.youtube.com/@drteplinsky Dr. Eleonora Teplinsky (X) https://x.com/drteplinsky INTERLUDE: Cancer Stories with Dr. Teplinsky (Apple Podcasts) https://podcasts.apple.com/us/podcast/interlude-cancer-stories-with-dr-teplinsky/id1451816690 Living Beyond Breast Cancer https://www.lbbc.org/ Books: “Beyond the Pink: Navigating Life, Health, and Breast Cancer,” by Dr. Eleonora Teplinsky https://www.hachettebookgroup.com/titles/dr-eleonora-teplinsky-m-d/beyond-the-pink/9781538777145/ “The New Perimenopause,” by Dr. Mary Claire Haver https://thepauselife.com/pages/the-new-perimenopause-book “The New Menopause,” by Dr. Mary Claire Haver https://www.amazon.com/dp/B0CKBZ4K1Z Never miss an episode—sign up for The ‘Pause Life Newsletter: https://thepauselife.com/pages/newsletter Medical Disclaimer: The information, including opinions and recommendations, on this platform is meant for informational and educational purposes only. Mary Claire Media, LLC, the unPAUSED podcast, and The ‘Pause Life are not medical organizations. Medical advice or medical diagnosis cannot be provided to you through the platform, any associated website, or customer portals. Using this platform does not establish a patient-physician relationship.

Transcript

0:00
37:20

7,022 words · 4 speakers

Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.

Topics

  • Aromatase inhibitors
  • Clarity
  • Polygenic risk scores
  • Tyracuzic model
  • Galleri test
  • Pernuvo scan
  • BRCA1
  • BRCA2
  • CACH2
  • ATM

Page updated · transcript and summary are machine-generated